Valuation dashboard for iSpecimen Inc. (ISPC) with P/E N/A, P/B 1.10, EV/EBITDA 0.39 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
iSpecimen Inc. operates a sophisticated technological platform that effectively bridges the gap between life science researchers and crucial human biological materials. Its proprietary cloud-based system empowers scientists to efficiently locate and access a vast array of biospecimens—such as biofluids, tissues, and living cells—as well as connect with potential study subjects, all sourced from a global network of healthcare providers, including hospitals, laboratories, bioba...
Analysis Summary
iSpecimen Inc. reported revenue of $1.9M in the most recent fiscal year, growing at a 5-year CAGR of -25.1%.
Trailing-twelve-month margins: gross margin -151.5%, operating margin -20.2%, net margin -24.5%.
At the current price of $1.37, ISPC has negative trailing earnings (P/E not meaningful) and an ROE of -5.24%. Market capitalisation stands at $0M.
Balance sheet quality for ISPC: current ratio of 1.1. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 1.10 |
| EV / EBITDA | 0.39 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $-53.30 |
| vs Current Price | -3990.8% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| ISPC | iSpecimen Inc. | 1.10 | -5.2% | ||
| 0R0H.L | Thermo Fisher Scientific Inc. | $241.2B | 35.21 | 4.62 | 13.4% |
| TMO | Thermo Fisher Scientific Inc. | $241.0B | 36.16 | 4.74 | 13.4% |
| 0R2B.L | Danaher Corporation | $148.7B | 47.40 | 3.26 | 6.9% |
| DHR | Danaher Corporation | $146.6B | 36.91 | 2.80 | 7.7% |
| NTRA | Natera, Inc. | $49.5B | 27.40 | -11.7% | |
| 0HAV.L | Agilent Technologies, Inc. | $49.3B | 30.43 | 5.93 | 20.5% |
| 0JDM.L | IQVIA Holdings Inc. | $46.0B |
Price
| Price | $1.37 |
| Market Cap | $0M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -524.37% |
| Return on Invested Capital | -476.39% |
| Return on Assets | -154.47% |
| Gross Margin | -151.47% |
| Operating Margin | -2020.04% |
| Net Margin | -2449.04% |
Related companies: BIAF · BIVI · BJDX · GLMD · HSCS · NDRA · SHPH
Explore sector: Healthcare · Medical - Diagnostics & Research
More sections of ISPC: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks